Location: Home >> Special Issue
Special Issue
Dear colleagues,
This special issue focuses on the groundbreaking advancements in vaccine development, with a particular emphasis on mRNA vaccines and their remarkable success in combating COVID-19. The rapid development and deployment of mRNA vaccines have revolutionized the field of immunization, showcasing the potential of this innovative technology in responding to global health crises. By gathering diverse research findings and insights, this special issue aims to foster collaboration and innovation in the field of vaccine development, paving the way for new therapeutic approaches that can effectively tackle current and emerging infectious diseases. We invite researchers, healthcare professionals, and industry leaders to contribute their work and perspectives on this crucial topic. It including but not limited to the following topics:
mRNA Vaccines
Vaccine Technology
Immunogenicity
Clinical Trials
Vaccine Efficacy
Adjuvants
Infectious Diseases
Vaccine Platforms
Antigen Design
Cold Chain Storage
Safety and Tolerability
Preclinical Studies
Serological Response
Vaccination Strategies
Herd Immunity
Authors should submit their manuscripts for the special issue by emailing them as an attachment to specialissue@hillpublish.com or by using the online submission system. The manuscript should be submitted by one of the authors, and submissions by anyone other than the authors will not be accepted. Additionally, the submitted manuscript should include a cover letter that specifies the special issue to which the manuscript is being submitted.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). The submitted papers should be properly formatted and written in fluent English. All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Guidelines page.
December 31, 2024